GoKawiilResearch continues into side effects of popular GLP-1 weight-loss drugs
GLP-1 agonist drugs, approved for diabetes, kidney disease and obesity, are being used by a growing share of Americans, with a recent Gallup poll finding 11% currently take one for weight loss, up from 3% in 2024. Beyond common gastrointestinal issues, pancreatitis and gallstones, researchers and lawsuits are examining rarer possible effects including eye nerve damage, plus emerging questions about hair and nail changes.
GoKawiil's interpretation of the reporting above, not reported fact.
The rapid rise in GLP-1 use means any undetected risks could affect millions of people, making ongoing safety research especially consequential. Lawsuits against Novo Nordisk and Eli Lilly over vision loss claims suggest legal and regulatory scrutiny could intensify even though the companies dispute a causal link and evidence remains mixed.
- 11% of Americans currently use GLP-1 drugs for weight loss, up from 3% in 2024
- Known side effects include gastrointestinal issues, pancreatitis and gallstones
- Researchers and lawsuits are probing possible links to eye nerve damage and hair/nail changes
Source: technologyreview.com — Jessica Hamzelou, 2026-10-09
Published there as: “We’re still figuring out the side effects of GLP-1 weight-loss drugs”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.